Palisade Bio to Present PALI-2108 Phase 1 Ulcerative Colitis Data Showing Biomarker Gains
Palisade Bio’s PALI-2108 data was selected for a poster at Digestive Disease Week 2026 on May 5, demonstrating clinical and biomarker improvements in ulcerative colitis from a Phase 1 study. The company is advancing PALI-2108 into a Phase 2 ulcerative colitis trial with a 12-week efficacy and maintenance extension assessment.
1. DDW Poster Presentation Details
Palisade Bio will present its PALI-2108 data in the Mechanisms of IBD Therapeutics poster session at Digestive Disease Week 2026 on May 5 from 12:30 PM to 1:30 PM CDT in Chicago’s McCormick Place Hall F2. Management will be available for one-on-one meetings with qualified investors to discuss translational findings.
2. Clinical Progress and Phase 2 Plans
PALI-2108, a once-daily oral PDE4 inhibitor prodrug designed for targeted gut delivery, demonstrated rapid clinical and biomarker improvements in ulcerative colitis during a Phase 1 trial. The company is now advancing the program into a Phase 2 study evaluating remission, response and pharmacodynamic biomarkers over a 12-week period with an extension phase for maintenance of remission.